HOUSTON, Dec. 10, 2019 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on behalf
of the MD Anderson Cancer Center ("MD Anderson"), today announced
the appointment of Mary Stoll as
Senior Director of Clinical Development. Ms. Stoll will have
responsibility for direct oversight of all clinical activities of
the Company's Rapid Acoustic Pulse ("RAP") device for tattoo
removal, improvement in the appearance of cellulite, keloid
(scarring), and additional pipeline indications.
Dr. Chris Capelli, Soliton's
President, CEO and co-founder, commented, "In line with our growth
plans, Mary is a welcomed addition to the Soliton team and her
appointment corresponds with our strategic increase in clinical
activity planned for 2020. Mary brings deep knowledge and related
experience, which gives me great confidence in our ability to
execute our on-going clinical strategy."
Mary Stoll joins Soliton from
Cytrellis Biosystems where she served as Senior Director of
Clinical Operations. At Cytrellis, she oversaw and lead all
clinical operations activities for new technology targeting skin
laxity and was responsible for promoting, executing, and
establishing clinical strategies in line with the Company's mission
and vision. Prior to her tenure with Cytrellis, she was the
Executive Director of Clinical Services at Cynosure, a laser
Company acquired by Hologic, Inc. Ms. Stoll holds a Bachelor in
Science Health and Science Studies and a nursing degree both from
Quinnipiac University.
"We believe Mary's directly-related clinical dermatology
experience will help Soliton accelerate and improve our research
and development activities. It is evident that Mary's experience
directly overlaps the role she will fill at Soliton," states
Joe Tanner, the Chief Operating
Officer, "but more importantly, we believe she is exactly the right
fit within our culture of strong teamwork."
Join our more than 200K fans here
to follow the Company: https://soly-investors.com
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first FDA cleared commercial product will use rapid
pulses of acoustic shockwaves as an accessory to lasers for the
removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in
bringing the Rapid Acoustic Pulse ("RAP") device to the market. The
Company believes this "Soliton" method has the potential to lower
tattoo removal costs for patients, while increasing profitability
to practitioners, compared to current laser removal methods.
Soliton is investigating potential additional capabilities of the
RAP technology in clinical and preclinical testing, including the
potential to improve the appearance of cellulite by creating
mechanical stress at the cellular level and inducing significant
collagen growth and the potential to treat keloid and hypertrophic
scars by targeting the stiffened environment in the intracellular
matrix.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability to successfully
complete the clinical trials planned for 2020. These
statements relate to future events, future expectations, plans and
prospects. Although Soliton believes that the expectations
reflected in such forward-looking statements are reasonable as of
the date made, expectations may prove to have been materially
different from the results expressed or implied by such
forward-looking statements. Soliton has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under in our SEC filings,
including under the heading "Item 1A. Risk Factors" in the Form
10-K for year ended December 31, 2018
we filed with the SEC and updated from time to time in our Form
10-Q filings and in our other public filings with the SEC. Any
forward-looking statements contained in this release speak only as
of its date. Soliton undertakes no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-appoints-mary-stoll-as-senior-director-of-clinical-development-300971903.html
SOURCE Soliton, Inc.